1. Short title This Act may be cited as the Binational Health Strategies Act of 2020 . 2. United States-Mexico Border Health Commission infectious disease preparedness The United States-Mexico Border Health Commission Act ( 22 U.S.C. 290n et seq.) is amended by inserting after section 5 ( 22 U.S.C. 290n–5 ) the following: 5A. Infectious disease preparedness (a) COVID–19 response Not later than 120 days after the date of the enactment of this section, and annually thereafter (for as long as the Commission, acting with the participation of members representing both the United States and Mexican sections, determines is necessary), the Commission shall submit to Congress a report on the United States-Mexico Border Area’s response (beginning on February 1, 2020) to COVID–19, including with respect to testing, contact tracing, and other infection prevention and control measures carried out in the United States-Mexico Border Area, in both the United States and Mexico. (b) COVID–19 binational plan (1) In general Not later than 60 days after the date of the enactment of this section, the Commission (acting with the participation of members representing both the United States and Mexican sections) shall develop, and publish on a public website of the Commission, a binational strategic plan that addresses, with respect to COVID–19, how— (A) the United States-Mexico Border Area should strengthen its response to COVID–19, with a focus on testing, contact tracing, and other infection prevention and control measures; (B) the effect of COVID–19 on the economic conditions in the United States-Mexico Border Area may be mitigated; (C) the sharing of relevant health data, with respect to COVID–19, including testing and positivity rates, between health agencies within the United States-Mexico Border Area can be strengthened